LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

AIMS: To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization. METHODS: The ongoing LEADER trial has enrolled 9340 people with type 2 diabetes and at high ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, G H, Hegedüs, L, Marso, S P, Nauck, M A, Zinman, B, Bergenstal, R M, Mann, J F E, Derving Karsbøl, J, Moses, A C, Buse, J B, Tuttle, R M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405040/
https://www.ncbi.nlm.nih.gov/pubmed/25656058
http://dx.doi.org/10.1111/dom.12444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405040/
https://www.ncbi.nlm.nih.gov/pubmed/25656058
http://dx.doi.org/10.1111/dom.12444

Ejemplares similares